Literature DB >> 16272756

Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1.

Naoko Kimura1, Satohiro Masuda, Yuko Tanihara, Harumasa Ueo, Masahiro Okuda, Toshiya Katsura, Ken-Ichi Inui.   

Abstract

Although metformin, a cationic agent for type II diabetes, shows its pharmacological effect in the liver, the drug is mainly eliminated into urine. The tissue selectivity based on the function of drug transporters is unclear. In the present study, the transport of metformin was examined using HEK293 cells transiently transfected with five human renal organic ion transporter cDNAs. Human OCT1 and OCT2, but not OAT1, OAT3 or OCT2-A, stimulated the uptake. A kinetic analysis of metformin transport demonstrated that the amount of plasmid cDNA for transfection was also important parameter to the quantitative elucidation of functional characteristics of transporters, and both human and rat OCT2 had about a 10- and 100-fold greater capacity to transport metformin than did OCT1, respectively. In male rats, the mRNA expression level of rOCT2 in the whole kidneys was 8-fold greater than that of rOCT1 in the whole liver. The in vivo distribution of metformin in rats revealed that the expression level of renal OCT2 was a key factor in the control of the concentrative accumulation of metformin in the kidney. These findings suggest that metformin is a superior substrate for renal OCT2 rather than hepatic OCT1, and renal OCT2 plays a dominant role for metformin pharmacokinetics.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16272756     DOI: 10.2133/dmpk.20.379

Source DB:  PubMed          Journal:  Drug Metab Pharmacokinet        ISSN: 1347-4367            Impact factor:   3.614


  107 in total

1.  Molecular mechanism of renal tubular secretion of the antimalarial drug chloroquine.

Authors:  Fabian Müller; Jörg König; Hartmut Glaeser; Ingrid Schmidt; Oliver Zolk; Martin F Fromm; Renke Maas
Journal:  Antimicrob Agents Chemother       Date:  2011-04-25       Impact factor: 5.191

2.  Gender-Related Differences in the Expression of Organic Cation Transporter 2 and its Role in Urinary Excretion of Metformin in Rats.

Authors:  Yan-Rong Ma; Hong-Yan Qin; Yong-Wen Jin; Jing Huang; Miao Han; Xing-Dong Wang; Guo-Qiang Zhang; Yan Zhou; Zhi Rao; Xin-An Wu
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2016-10       Impact factor: 2.441

3.  A prospective analysis of co-processed non-ionic surfactants in enhancing permeability of a model hydrophilic drug.

Authors:  Mohammed M Alvi; Parnali Chatterjee
Journal:  AAPS PharmSciTech       Date:  2013-12-20       Impact factor: 3.246

Review 4.  The role of pharmacogenetics in drug disposition and response of oral glucose-lowering drugs.

Authors:  N van Leeuwen; J J Swen; H-J Guchelaar; L M 't Hart
Journal:  Clin Pharmacokinet       Date:  2013-10       Impact factor: 6.447

5.  Multiple mechanisms of ligand interaction with the human organic cation transporter, OCT2.

Authors:  Jaclyn N Harper; Stephen H Wright
Journal:  Am J Physiol Renal Physiol       Date:  2012-10-03

6.  Brain organic cation transporter 2 controls response and vulnerability to stress and GSK3β signaling.

Authors:  T Couroussé; A Bacq; C Belzung; B Guiard; L Balasse; F Louis; A-M Le Guisquet; A M Gardier; A H Schinkel; B Giros; S Gautron
Journal:  Mol Psychiatry       Date:  2014-08-05       Impact factor: 15.992

7.  Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action.

Authors:  Yan Shu; Steven A Sheardown; Chaline Brown; Ryan P Owen; Shuzhong Zhang; Richard A Castro; Alexandra G Ianculescu; Lin Yue; Joan C Lo; Esteban G Burchard; Claire M Brett; Kathleen M Giacomini
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

Review 8.  Pharmacogenetics of metformin response: a step in the path toward personalized medicine.

Authors:  Marc L Reitman; Eric E Schadt
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

9.  A proposal regarding reporting of in vitro testing results.

Authors:  Malcolm A Smith; Peter Houghton
Journal:  Clin Cancer Res       Date:  2013-04-11       Impact factor: 12.531

10.  Pharmacokinetic interaction between DA-8159, a new erectogenic, and metformin in rats: competitive inhibition of metabolism via hepatic CYP3A1/2.

Authors:  Y H Choi; S J Chung; M G Lee
Journal:  Br J Pharmacol       Date:  2008-01-21       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.